EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.
About 10% of patients with non-small cell lung carcinoma (NSCLC) respond to epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs). More than 75% of "responders" have activating mutations in EGFR. However, mutation analysis is not widely available, and proposed alternatives (in situ hybridization and immunohistochemical analysis) have shown inconsistent associations with outcome. Fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), immunohistochemical analysis, and DNA sequencing were compared in this study of 40 NSCLC samples from TKI-treated patients. Response rates were 12 of 19 in EGFR-mutant vs 1 of 20 EGFR wild-type tumors (P = .0001), 7 of 19 FISH+ vs 4 of 17 FISH- tumors (not significant [NS]), 5 of 16 CISH+ vs 6 of 21 CISH- tumors (NS), and 3 of 9 immunohistochemically positive vs 7 of 22 immunohistochemically negative tumors (NS). EGFR mutation was associated with improved progression-free survival (P = .0004). Increased copy number (FISH or CISH) and protein expression (immunohistochemical) did not independently predict outcome. Thus, EGFR sequence analysis was the only method useful for predicting response and progression-free survival following TKI therapy in NSCLC.
Sholl
Lynette M
LM
Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
Xiao
Yun
Y
Joshi
Victoria
V
Yeap
Beow Y
BY
Cioffredi
Leigh-Anne
LA
Jackman
David M
DM
Lee
Charles
C
Jänne
Pasi A
PA
Lindeman
Neal I
NI
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA
D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases
Cancer Res. 1992 May 1;52(9 Suppl):2702s-2706s
1314134
Clin Cancer Res. 2009 Aug 15;15(16):5267-73
19671843
Clin Cancer Res. 2009 Jul 1;15(13):4493-8
19531624
J Mol Diagn. 2008 May;10(3):242-8
18403609
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
J Clin Oncol. 2007 Mar 1;25(7):760-6
17228019
N Engl J Med. 2005 Feb 24;352(8):786-92
15728811
J Clin Oncol. 2006 Jul 20;24(21):3340-6
16785471
Am J Clin Pathol. 2006 Jun;125(6):860-5
16690485
Br J Cancer. 1987 May;55(5):513-6
3038157
J Clin Oncol. 2008 Sep 10;26(26):4268-75
18626007
JAMA. 2003 Oct 22;290(16):2149-58
14570950
J Clin Oncol. 2005 Oct 1;23(28):6829-37
15998907
Nature. 2008 Oct 23;455(7216):1069-75
18948947
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
15329413
J Clin Oncol. 2006 Nov 1;24(31):5034-42
17075123
Science. 2004 Aug 20;305(5687):1163-7
15284455
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s
16857818
N Engl J Med. 2009 Sep 3;361(10):958-67
19692684
Mod Pathol. 2007 Oct;20(10):1028-35
17673923
J Clin Oncol. 2005 Nov 1;23(31):8081-92
16204011
J Clin Oncol. 2006 Jan 1;24(1):64-9
16382114
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
Cancer. 2008 Mar 1;112(5):1114-21
18219661
Mod Pathol. 2009 Jan;22(1):128-33
18997733
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
18093943
Lung Cancer. 2007 Jun;56(3):383-9
17368623
J Clin Oncol. 2008 Mar 20;26(9):1472-8
18349398
J Clin Oncol. 2008 May 20;26(15):2442-9
18458038
Science. 2004 Jun 4;304(5676):1497-500
15118125
Ann Oncol. 2007 Apr;18(4):752-60
17317677
J Clin Oncol. 2005 Oct 1;23(28):6838-45
15998906
Cancer Res. 2008 Apr 1;68(7):2106-11
18381415
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Science. 2007 May 18;316(5827):1039-43
17463250
Br J Cancer. 2004 Jul 19;91(2):208-12
15187994
PLoS Med. 2005 Mar;2(3):e73
15737014
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
15741570
Cancer Prev Res (Phila). 2008 Aug;1(3):192-200
19138956
J Natl Cancer Inst. 2005 May 4;97(9):643-55
15870435